MedPath
HSA Product

SPIRIDON TABLETS 100MG

Product approved by Health Sciences Authority (SG)

Basic Information

SPIRIDON TABLETS 100MG

TABLET

Regulatory Information

SIN16709P

February 23, 2023

Prescription Only

Therapeutic

ORAL

August 10, 2023

May 30, 2025

XC03DA01

Company Information

ORION PHARMA (SG) PTE. LTD.

ORION PHARMA (SG) PTE. LTD.

Active Ingredients

Spironolactone

Strength: 100.0mg

Detailed Information

Contraindications

**4.3 Contraindications** Spironolactone is contraindicated in adults and children in the following cases: - acute renal insufficiency, significant renal compromise, anuria - Addison’s disease - hyperkalaemia - hypersensitivity to spironolactone - concomitant use of eplerenone. Spironolactone is contraindicated in children with moderate to severe renal insufficiency.

Indication Information

**4.1 Therapeutic indications** Spironolactone is indicated for the following: - Congestive cardiac failure - Hepatic cirrhosis with ascites and oedema - Malignant ascites - Nephrotic syndrome - Diagnosis and treatment of primary aldosteronism. Children should only be treated under guidance of a paediatrician. There is limited paediatric data available (see section 5.1 and 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

© Copyright 2025. All Rights Reserved by MedPath